Literature DB >> 22124666

Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.

Claudia Stöllberger, Josef Finsterer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22124666     DOI： 10.1007/s00415-011-6328-y

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  8 in total

1.  ACP Journal Club. Dabigatran led to less major bleeding than warfarin in younger but not older patients with atrial fibrillation.

Authors:  Marcel Levi
Journal:  Ann Intern Med       Date:  2011-09-20       Impact factor: 25.391

2.  The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation.

Authors:  L Jungbauer; C Dobias; C Stöllberger; F Weidinger
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

3.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

4.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy
Journal:  J Am Coll Cardiol       Date:  2011-02-14       Impact factor: 24.094

5.  Dabigatran in patients with nonvalvular atrial fibrillation.

Authors:  Lawrence Gage
Journal:  J Am Coll Cardiol       Date:  2011-07-26       Impact factor: 24.094

6.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

7.  The use of dabigatran in elderly patients.

Authors:  Matthieu Legrand; Joaquim Mateo; Alice Aribaud; Sixtine Ginisty; Pirayeh Eftekhari; Patrice Tran Ba Huy; Ludovic Drouet; Didier Payen
Journal:  Arch Intern Med       Date:  2011-07-25

8.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245
  8 in total
  1 in total

1.  Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry.

Authors:  Georgios Tsivgoulis; Christos Krogias; Kara A Sands; Vijay K Sharma; Aristeidis H Katsanos; Konstantinos Vadikolias; Sokratis G Papageorgiou; Ioannis Heliopoulos; Harn Shiue; Athina Mitsoglou; Chrissoula Liantinioti; Dimitrios Athanasiadis; Sotirios Giannopoulos; Charitomeni Piperidou; Konstantinos Voumvourakis; Andrei V Alexandrov
Journal:  Ther Adv Neurol Disord       Date:  2014-05       Impact factor: 6.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.